Abstract：
Non-coding RNAs are mainly divided into two categories, one is small non-coding RNA represented by miRNA, and the other is long non-coding RNA longer than 200 bp. Further studies on non-coding RNAs have revealed that long non-coding RNAs not only have carcinogenic effects, but also have potential links with miRNAs. Antisense non-coding RNA in the INK4 locus (ANRIL/CDKN2B-AS1), one of the five subtypes of long non-coding RNA, has been proved to play a role of oncogene in many cancers, such as gastric cancer, cervical cancer, prostate cancer and non-small cell lung cancer. Knockdown ANRIL can significantly inhibit the proliferation and migration of cancer cells, while also negatively regulating the expression of related miRNAs. This suggests that ANRIL may serve as a potential target for the development of drugs that provide new strategies to improve the effectiveness of cancer treatment. In our review, we summarize the current association between ANRIL and miRNAs in various cancers.
摘要：
非编码RNA主要分为两类,一种是由miRNA代表的非编码小RNA，另一种是长度超过200bp的非编码RNA。对非编码RNA的进一步研究表明，长链非编码RNA不仅具有致癌作用，但也与miRNA有潜在的联系。INK4基因座中的反义非编码RNA（ANRIL/CDKN2B-AS1），长链非编码RNA的五种亚型之一,已被证明在许多癌症中发挥癌基因的作用，比如胃癌，宫颈癌,前列腺癌和非小细胞肺癌。敲除ANRIL可以显著抑制癌细胞的增殖和迁移，同时也负调控相关miRNA的表达。这表明ANRIL可以作为开发药物的潜在靶标，这些药物提供了提高癌症治疗有效性的新策略。在我们的审查中,我们总结了目前在各种癌症中ANRIL和miRNAs之间的关联。
